Janet Tu, MD
Internal Medicine · Sugar Land, TXNPI 1275787988
Payments from drug & device makers
What this record shows
7 manufacturers reported payments, led by Pfizer at 47.9% of the total.
Across 22 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$182
- Novocure Inc.$70
- Jazz Pharmaceuticals Inc.$60
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$24
- Daiichi Sankyo Inc.$19
- Amgen$13
- plus $12 from 1 others
Across 8 payments — averaging $137,648 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.1M
What the payments were for
- Food & beverage$18649%
- Education$19451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $182 |
| Novocure Inc. | 1 | $70 |
| Jazz Pharmaceuticals Inc. | 1 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Amgen | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$381 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 38 | $642,600 |
| AlecensaAlectinib Hcl | 11 | $208,003 |
| Dexamethasone | 31 | $526 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $298 |
| Gabapentin | 18 | $287 |
| Ondansetron Hcl | 37 | $231 |
| Potassium Chloride | 11 | $121 |
| Hydroxyurea | 13 | $120 |
| Levothyroxine Sodium | 16 | $39 |
| Prednisone | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Sugar Land
- Spencer BerthelsenSugar Land$891K
- Bartley GillSugar Land$218K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.